Meeting
2016 Gastrointestinal Cancers Symposium
A phase II study of biweekly gemcitabine at fixed dose rate infusion plus S1 as first-line chemotherapy in patients with locally advanced or metastatic pancreatic cancer.
Authors
Xj Xiang
Department of Oncology, First Affiliated Hospital of Nanchang University, Nanchang, China
Xj Xiang , L Zhang , Jh Li , Zy Zhan , M Feng , J Chen , JP Xiong
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 34, 2016 (suppl 4S; abstr 357)
DOI
10.1200/jco.2016.34.4_suppl.357
Abstract #
357
Poster Bd #
H15
Abstract Disclosures
Similar Posters
Poster
2015 Gastrointestinal Cancers Symposium
A phase II clinical trial of carbon-ion radiotherapy and concurrent S-1 chemotherapy for locally advanced pancreatic cancer.
First Author: Makoto Shinoto
Poster
2024 ASCO Gastrointestinal Cancers Symposium
DIsCOvER: A multicenter, randomized, double-blind, placebo-controlled, phase III clinical trial to investigate the efficacy and safety of dronabinol in the improvement of chemotherapy-induced and tumor-related symptoms in patients with locally advanced or metastatic pancreas cancer during first-line chemotherapy.
First Author: Felix Keil
Poster
2021 Gastrointestinal Cancers Symposium
Silmitasertib (CX-4945) in combination with gemcitabine and cisplatin as first-line treatment for patients with locally advanced or metastatic cholangiocarcinoma: A phase Ib/II study.
First Author: Mitesh J. Borad
Poster
2020 ASCO Virtual Scientific Program
A randomized phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy.
First Author: Jin Won Kim